Solara Active Pharma Sciences Limited has issued a revised intimation regarding its upcoming conference call with analysts and investors to discuss Q3FY26 financial results. The pharmaceutical company filed the updated notification with BSE and NSE on February 03, 2026, announcing a change in the timing of the previously scheduled earnings call.

Revised Conference Call Details

The company has updated the earnings call schedule with the following revised specifications:

Key Management Participation

The earnings call will feature senior management representatives who will discuss the company's performance:

• Arun Kumar - Founder & Non-Executive Director
• Sandeep Rao - Managing Director & CEO
• Sarat Kumar - Chief Financial Officer

Financial Results Coverage

The conference call will cover Solara Active Pharma Sciences' unaudited financial results for the quarter and nine months ended December 31, 2025. This represents the company's Q3FY26 performance, providing insights into the pharmaceutical company's operational and financial metrics during this period.

Access Information

The company has provided multiple access options for participants:

The revised intimation was signed by Pooja Jaya Kumar, Company Secretary & Compliance Officer (Membership No: A57415), and filed under Regulation 30 compliance requirements with both BSE (Scrip Code: 541540, 890202) and NSE (Symbol: SOLARA, SOLARAPPI). All other details from the original intimation dated January 30, 2026, remain unchanged except for the timing modification.

Solara Active Pharma Sciences has announced the reconstitution of its Management Committee following a board meeting held on December 17, 2025. The company communicated this development to BSE Limited and National Stock Exchange of India Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The Board of Directors approved the reconstitution of the Management Committee during their meeting on December 17, 2025. The decision was made to enhance governance structure and operational efficiency of the pharmaceutical company.

Management Committee Composition

The reconstituted Management Committee comprises three key members representing different levels of the organizational hierarchy, ensuring comprehensive oversight and decision-making capabilities.

Corporate Structure

The Management Committee reconstitution reflects the company's commitment to maintaining robust governance standards. Mr. Arun Kumar Pillai will lead the committee as Chairperson in his capacity as Non-Executive Director, while the Managing Director & CEO and Chief Financial Officer will serve as key members.

Regulatory Compliance

Solara Active Pharma Sciences has fulfilled its disclosure obligations by informing both major stock exchanges about the committee reconstitution. The company operates from its corporate office at TICEL Bio Park, Chennai, and maintains its registered office in Navi Mumbai.

The reconstitution demonstrates the company's ongoing efforts to strengthen its management structure and ensure effective oversight of operations across its pharmaceutical business segments.